Importantly, similarly to the XLIX-treated HFD mouse model, the level of phospho-PPP1CB (Thr316) was increased in the XLIX-treated NASH mouse group (Fig. 7m). Here, PPP1CB is linked to metabolic dysfunction-associated steatohepatitis.